Autonomix Medical Announces Preliminary Results From First Five Patients In PoC Trial For Pancreatic Cancer Pain
Portfolio Pulse from Benzinga Newsdesk
Autonomix Medical announced promising preliminary results from its PoC trial for pancreatic cancer pain. The first five patients experienced significant pain relief with no major complications. The trial is on track to complete enrollment by the end of 2024.
June 18, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Autonomix Medical's preliminary trial results for pancreatic cancer pain show significant pain relief and no major complications, which could positively impact the stock price.
The preliminary results indicate a high success rate in pain relief with no significant adverse events, which is a positive development for Autonomix Medical. This could lead to increased investor confidence and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100